Celldex Therapeutics (CLDX) Competitors $26.30 +0.10 (+0.38%) (As of 11:33 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends CLDX vs. MDGL, HALO, IONS, ALKS, FOLD, LGND, GERN, MNKD, DVAX, and BCRXShould you be buying Celldex Therapeutics stock or one of its competitors? The main competitors of Celldex Therapeutics include Madrigal Pharmaceuticals (MDGL), Halozyme Therapeutics (HALO), Ionis Pharmaceuticals (IONS), Alkermes (ALKS), Amicus Therapeutics (FOLD), Ligand Pharmaceuticals (LGND), Geron (GERN), MannKind (MNKD), Dynavax Technologies (DVAX), and BioCryst Pharmaceuticals (BCRX). These companies are all part of the "biotechnology" industry. Celldex Therapeutics vs. Madrigal Pharmaceuticals Halozyme Therapeutics Ionis Pharmaceuticals Alkermes Amicus Therapeutics Ligand Pharmaceuticals Geron MannKind Dynavax Technologies BioCryst Pharmaceuticals Celldex Therapeutics (NASDAQ:CLDX) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability. Does the media prefer CLDX or MDGL? In the previous week, Madrigal Pharmaceuticals had 2 more articles in the media than Celldex Therapeutics. MarketBeat recorded 6 mentions for Madrigal Pharmaceuticals and 4 mentions for Celldex Therapeutics. Madrigal Pharmaceuticals' average media sentiment score of 1.41 beat Celldex Therapeutics' score of 1.27 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celldex Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Madrigal Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, CLDX or MDGL? Celldex Therapeutics has a beta of 1.57, meaning that its stock price is 57% more volatile than the S&P 500. Comparatively, Madrigal Pharmaceuticals has a beta of -0.42, meaning that its stock price is 142% less volatile than the S&P 500. Is CLDX or MDGL more profitable? Madrigal Pharmaceuticals has a net margin of 0.00% compared to Celldex Therapeutics' net margin of -1,544.32%. Celldex Therapeutics' return on equity of -19.75% beat Madrigal Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Celldex Therapeutics-1,544.32% -19.75% -18.86% Madrigal Pharmaceuticals N/A -71.78%-53.25% Which has preferable valuation and earnings, CLDX or MDGL? Celldex Therapeutics has higher earnings, but lower revenue than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Celldex Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCelldex Therapeutics$6.88M252.63-$141.43M-$2.57-10.19Madrigal Pharmaceuticals$76.81M88.30-$373.63M-$25.08-12.40 Do institutionals and insiders believe in CLDX or MDGL? 98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. 3.8% of Celldex Therapeutics shares are held by company insiders. Comparatively, 22.8% of Madrigal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts prefer CLDX or MDGL? Celldex Therapeutics presently has a consensus target price of $62.25, suggesting a potential upside of 137.60%. Madrigal Pharmaceuticals has a consensus target price of $347.33, suggesting a potential upside of 11.69%. Given Celldex Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Celldex Therapeutics is more favorable than Madrigal Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Celldex Therapeutics 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.89Madrigal Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.69 Does the MarketBeat Community believe in CLDX or MDGL? Celldex Therapeutics received 160 more outperform votes than Madrigal Pharmaceuticals when rated by MarketBeat users. Likewise, 75.15% of users gave Celldex Therapeutics an outperform vote while only 67.70% of users gave Madrigal Pharmaceuticals an outperform vote. CompanyUnderperformOutperformCelldex TherapeuticsOutperform Votes61775.15% Underperform Votes20424.85% Madrigal PharmaceuticalsOutperform Votes45767.70% Underperform Votes21832.30% SummaryCelldex Therapeutics beats Madrigal Pharmaceuticals on 12 of the 19 factors compared between the two stocks. Ad Weiss Ratings“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.Learn these 4 simple steps and protect your savings before it’s too late. Get Celldex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CLDX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLDX vs. The Competition Export to ExcelMetricCelldex TherapeuticsDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.74B$2.74B$4.97B$9.34BDividend YieldN/A0.74%4.78%4.04%P/E Ratio-10.195.71134.8617.59Price / Sales252.6392.511,232.5583.29Price / CashN/A15.1640.8738.32Price / Book2.893.484.924.93Net Income-$141.43M$31.95M$117.85M$225.54M7 Day Performance-1.17%-3.35%12.53%-1.11%1 Month Performance11.25%16.17%15.85%5.67%1 Year Performance-29.48%-21.69%35.28%22.97% Celldex Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLDXCelldex Therapeutics3.0716 of 5 stars$26.30+0.4%$62.25+136.7%-29.5%$1.74B$6.88M-10.23160Positive NewsMDGLMadrigal Pharmaceuticals4.3086 of 5 stars$309.61+1.7%$347.33+12.2%+31.1%$6.75BN/A-12.1490Positive NewsHALOHalozyme Therapeutics4.9958 of 5 stars$48.12+0.3%$61.11+27.0%+23.1%$6.12B$947.36M15.98390Short Interest ↓Positive NewsIONSIonis Pharmaceuticals4.4853 of 5 stars$38.54+5.3%$60.65+57.4%-23.3%$6.09B$803.07M-15.00800Short Interest ↓Positive NewsALKSAlkermes4.6751 of 5 stars$30.48-0.1%$35.42+16.2%+11.9%$4.93B$1.51B15.652,100Short Interest ↓FOLDAmicus Therapeutics4.3948 of 5 stars$9.84+5.1%$16.88+71.5%-22.2%$2.94B$493.67M-28.71480LGNDLigand Pharmaceuticals4.8899 of 5 stars$123.17+5.4%$147.00+19.3%+81.6%$2.33B$152.42M47.4480Analyst ForecastAnalyst RevisionNews CoverageGERNGeron3.926 of 5 stars$3.80-1.6%$7.15+88.2%+69.3%$2.30B$29.48M-12.06141Short Interest ↓MNKDMannKind3.6386 of 5 stars$6.32-3.4%$8.67+37.1%+59.1%$1.74B$267.20M89.29400News CoverageDVAXDynavax Technologies4.8046 of 5 stars$13.00+0.3%$22.00+69.2%-5.9%$1.71B$260.81M100.00408Short Interest ↓News CoveragePositive NewsBCRXBioCryst Pharmaceuticals3.8977 of 5 stars$7.42-1.5%$15.60+110.2%+20.5%$1.54B$412.58M-12.34530Positive News Related Companies and Tools Related Companies Madrigal Pharmaceuticals Alternatives Halozyme Therapeutics Alternatives Ionis Pharmaceuticals Alternatives Alkermes Alternatives Amicus Therapeutics Alternatives Ligand Pharmaceuticals Alternatives Geron Alternatives MannKind Alternatives Dynavax Technologies Alternatives BioCryst Pharmaceuticals Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CLDX) was last updated on 12/17/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celldex Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Celldex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CLDX Stock Alerts